Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Three Patent Applications Related to RNAi: May 17, 2007

Title: Bioinformatically Detectable Group of Novel HIV Regulatory Genes and Uses Thereof
Numbers: 7,217,807
Filed: Aug. 28, 2003
Inventor: Isaac Bentwich, Rosetta Genomics
The patent, its abstract states, relates to “a group of novel viral RNA regulatory genes, here identified as viral genomic address messenger genes or VGAM genes, and … genomic record or GR genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease,” the abstract states. “Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.”

Title: Gene Expression Suppression Agents
Numbers: 20070105795
Filed: May 12, 2003 PCT Filed: May 12, 2003
Lead Inventor: Yingxian Xiao, Potomac Pharmaceuticals
According to the patent application’s abstract, the invention comprises “a method … for making gene suppression agents to be used in eukaryotic cells by using a recombinant DNA construct containing at least one transcriptional unit compromising a transcriptional promoter, a template sequence for making a RNA molecule, and a transcriptional terminator. Mechanisms of the RNA mediated gene suppression include, but [are] not limited to, RNA interferences. The use of the agents as tools for biomedical research as well as medicinal products is also disclosed,” the abstract adds.

Title: Methods of Degrading dsRNA and Synthesizing RNA
Numbers: 20070105113
Filed: Aug. 10, 2004 PCT Filed: Aug. 10, 2004
Lead Inventor: Hiroaki Sagawa, Takara Bio
The patent application, it’s abstract states, claims “a protein having an activity of degrading a dsRNA, namely, being capable of acting on a long-chain dsRNA to form a dsRNA of a definite length; a method of efficiently preparing a dsRNA of a definite length which comprises treating a dsRNA with the protein having an activity of degrading a dsRNA in the coexistence of a protein having an activity of binding to a nucleic acid such as a protein having an RNA-binding activity; and a method of using the protein having an activity of binding to a nucleic acid to elevate the efficiency in an RNA synthesis reaction typified by dsRNA synthesis.”

Title: Small Interfering RNA-Mediated Transcriptional Gene Silencing in Mammalian Cells
Numbers: 20070104688
Filed: May 24, 2006
Lead Inventor: John Rossi, City of Hope
The invention, the patent application’s abstract states, “relates to transcriptional gene silencing in mammalian, including human, cells that [are] mediated by small interfering RNA molecules. The present invention also relates to a method for directing histone and/or DNA methylation in mammalian, including human, cells. It has been found that siRNAs can be used to direct methylation of DNA in mammalian, including human, cells.”

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.